BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lunbotinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lunbotinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05265091-2472@assetmemo.bio
DTSTAMP:20261121T005443Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lunbotinib: Phase 1/2 readout est. (NCT05265091)
DESCRIPTION:Lunbotinib\, phase 1/2.\nStudy: A Study of KL590586 in Patients
  With Advanced Solid Tumors\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/lunbotinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05265091
URL:https://assetmemo.bio/drug/lunbotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05443126-2472@assetmemo.bio
DTSTAMP:20261121T005443Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lunbotinib: Phase 1/2 readout est. (NCT05443126)
DESCRIPTION:Lunbotinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Maligna
 ncies\nEstimated primary completion: March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/lunbotinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05443126
URL:https://assetmemo.bio/drug/lunbotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
